NASDAQ: BCTXBriacell Therapeutics Corp Stock
$7.12+0.20 (+2.89%)
Updated Mar 29, 2023
BCTX Price
$7.12
Fair Value Price
$9.28
Market Cap
$110.49M
52 Week Low
$4.06
52 Week High
$12.09
P/E
-3.15x
P/B
-86.28x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$35.01M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-27.68
Operating Cash Flow
-$17M
Beta
1.22
Next Earnings
Mar 30, 2023
Ex-Dividend
N/A
Next Dividend
N/A
BCTX Overview
BriaCell Therapeutics Corp. develops immunotherapies for the treatment of cancer. Its lead candidate, Bria-IMT, is in Phase I/IIa clinical trials for the treatment of breast cancer. The company has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, personalized immunotherapy for advanced breast cancer, and BriaDx, a diagnostic test. BriaCell Therapeutics is headquartered in West Vancouver, Canada.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BCTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BCTX ($7.12) is undervalued by 23.27% relative to our estimate of its Fair Value price of $9.28 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BCTX ($7.12) is significantly undervalued by 23.27% relative to our estimate of its Fair Value price of $9.28 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BCTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCTX due diligence checks available for Premium users.
Be the first to know about important BCTX news, forecast changes, insider trades & much more!
BCTX News
Valuation
BCTX fair value
Fair Value of BCTX stock based on Discounted Cash Flow (DCF)
Price
$7.12
Fair Value
$9.28
Undervalued by
23.27%
BCTX ($7.12) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCTX ($7.12) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BCTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.15x
Industry
18.17x
Market
21.81x
BCTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-86.28x
Industry
4.92x
BCTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$11.9M
Profit Margin
0%
BCTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$34.2M
Liabilities
$35.4M
Debt to equity
-27.68
BCTX's short-term assets ($33.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCTX's long-term liabilities ($34.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BCTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.0M
Investing
$0.0
Financing
$0.0
BCTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BCTX vs Biotech Stocks
Briacell Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.